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824-4 Echocardiographic Findings in Patients Undergoing 
Percutaneous Aortic Valve Replacement
Fabrice Bauer, Hélène Eltchaninoff, Christophe Tron, Carla Agatiello, Laurent Sebagh, 
Alain Cribier, Hôpital Charles Nicolle, Rouen, France
Background: Percutaneous valve replacement (PVR) has been recently shown to be fea-
sible in human. A new percutaneous heart valve (PHV) made of 3 leaflets of equine peri-
cardium inserted in a stainless steel stent was successfully implanted within the native
diseased valve of 5 non-operable Pts (4 males, mean aged 75+12) with end stage calcific
aortic stenosis (AS). Assessment by transthoracic and transesophageal echocardio-
graphy of PHV function within the native diseased calcific valve are reported.
Methods and Results: Functional aortic valve area (AVA) by continuity equation, mean
trans-PHV pressure gradient (MG) and left ventricular ejection fraction (LVEF) were mea-
sured before, immediately post-PVR and sequentially during follow-up. Results are
shown in the table (* p<0,05 as compared to baseline).
Overtime, there was no PHV dislodgment, no change in paravalvular leak (mild in 3,
severe in two) noted post-PVR and PHV leaflets remained thin and mobile within a cylin-
drical stent frame.
Conclusions: Transthoracic and transesophageal echocardiography are the optimal way
to assess PHV function after PVR. Immediate and sustained valvular function and hemo-
dynamic improvements were observed, making this new technique promising for non-
surgical Pts with AS.
5:00 p.m.
824-5 Percutaneous Aortic Valve Replacement With a Self-
Expandable Stent-Valve in the Beating Heart: In Vivo 
Stress Testing in an Animal Model
Markus Ferrari, Gerhard Hellige, Markus Schlosser, Gerald S. Werner, Ines Frerichs, 
Christoph Damm, Volker Guyenot, Hans R. Figulla, Friedrich-Schiller-University, Jena, 
Germany, Georg-August-University, Goettingen, Germany
Introduction: Due to an increasing number of elderly patients with relevant co-morbidity
there is need for a non-invasive technique of aortic valve replacement. Therefore, we
evaluated the feasibility of percutaneous aortic valve replacement without cardiac arrest
in animal experiments.
Methods: Pulmonary valves from pigs were sutured in a self-expanding stent after low-
pressure fixation in Glutaraldehyd solution. The Nitinol stent, containing the biological
valve in its proximal part, was implanted in six pigs (88-118 kg) by means of a 25F cathe-
ter via the left subclavian artery by guidance of fluoroscopy and trans-esophageal
echocardiography (TEE). The original aortic valve was pushed against the aortic wall by
the self-expanding stent during the implantation.
Results: It was possible to replace the aortic valve in the beating heart without any com-
plication or even relevant drops in blood pressure in 4 pigs (67 %) . The procedure failed
in 2 pigs (33 %) due to failure of the catheter device in one case, and due to problems
with the correct positioning in the left ventricular outflow tract in the other case. The first
pig died of bleeding complications, the second pig died of an acute aortic insufficiency. In
the remaining four pigs we infused catecholamines: Cardiac output doubled compared to
baseline conditions. Heart rate increased to 158 +/-31 /min., and aortic pressure reached
149+/-3.4 mmHg. We did not observe any relevant aortic insufficiency by TEE, nor an
increase of peak aortic flow above 1.7 m/s.
Conclusion: This study proves the feasibility of percutaneous aortic valve replacement in
the beating heart, and shows the safety of the device under pathophysiologic stress con-
ditions. By further diameter reduction of the implantation-catheter-device, and chronic
animal experiments this concept might become a feasible option for treating patients with
relevant aortic valve disease but a high operative risk.
5:15 p.m.
824-6 Percutaneous Implantation of a Heart Valve: An Animal 
Study
David Paniagua, Eduardo Induni, Orlando Puente, Carlos Mejia, Carolyne Ortiz, Jose A. 
Condado, Manuel Velez, Martha Borbon, Elizabeth Gonzalez, R. David Fish, 
Endoluminal Technology Research, Miami Beach, FL, Texas Heart Institute/ St Luke's 
Episcopal Hosptial, Houston, TX
Background. 
Percutaneous heart valve (PHV) implantation is an emerging form of therapy for valve
disease. We developed a new low profile folded pericardial PHV deliverable with catheter
techniques. The initial acute and long term animal data is described.
Methods
Eleven sheep and six calves weighing 30 to 60 kg underwent transcatheter implantation
of a PHV. Vascular access via the femoral or carotid artery was employed. Introduction of
the PHV was performed using a customized delivery system and angiographic guidance.
Transthoracic Echo-Doppler assessment was used.
Results 
Eight chronic and 9 acute animal studies were performed. The PHV was implanted in the
descending aorta (11 animals), and in the ascending aorta (6 animals). Deployment of
the PHV in the selected position was made under fluoroscopic guidance using a balloon
expandable stent in one case and a self-expanded stent in 16 cases oversized by 10% to
have the required radial force to hold the valve in place without migration. No migration of
the stented valves has occurred. Pathological examination of the implantation site
showed ecchymosses and superficial hemorrhage without evidence of perforation or dis-
section. One animal died acutely of vascular complications. One stent did not open caus-
ing aortic thrombosis and death of the animal. One calf was sacrificed 3 weeks after
implantation. Function of the harvested PHV was competent in the left heart simulator
and histology showed no evidence of rejection. One calf is 8 months post implant of a self
expanded stented valve that has grown with him, he is clinically well. In the last 4 sheep,
the PHV was introduced through the carotid artery and placed in the ascending aorta.
Valves placed in this anatomical area are responsible for preventing leakage of 2/3 of the
diastolic pressure. The sheep recovered in less than 2 hours. These sheep are 3 months
post procedure in good clinical conditions and the valves are functioning properly by Dop-
pler study that shows forward flow without evidence of regurgitation.
Conclusion
Percutaneous implantation of this new PHV is feasible and well tolerated in sheep and
calf models, and show normally competent hemodynamic behaviour. Long term histology
is to follow.
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1125-135 Valve Renovation in Calcific Aortic Stenosis: Safety and 
Feasibility of a Novel Endoaortic System for Native 
Valve Preservation
Jerome B. Riebman, Kevin L. Ohashi, Robert D. Poser, Gerry J. Berry, Ajit P. Yoganathan, 
Corazon Technologies, Inc., Menlo, CA, Stanford University, Stanford, CA
BACKGROUND – Mineral removal using a low-pH saline solution treatment (demineral-
ization) may be a safe, predictable repair technique for calcified stenotic aortic valves
(AVs). In vivo and ex vivo safety and efficacy of an endoaortic system for in situ treatment
of calcified stenotic AVs was investigated.
METHODS – Excised human AV leaflets (n = 24) and intact calcified stenotic AVs (n=12)
were treated with demineralization solution in stages for up to 60 minutes. Treated leaf-
lets underwent biochemical and histological analysis to determine ex vivo safety.
Endoaortic treatment efficacy in intact AVs was assessed by pre- and post-treatment
hemodynamic, radiographic, and video motion analysis in a flow loop at multiple levels of
physiologic loading. Mineral removed and total mineral content of specimens was quanti-
fied using atomic absorption spectroscopy. In vivo safety was assessed in an ovine
model by exposing their normal AVs (n = 18) to the demineralization solution with the
endoaortic system ( 30 minutes) followed by serial cardiac echocardiography and histol-
ogy up to 9 months.
RESULTS – Human leaflet histology revealed preserved normal tissue architecture. Bio-
chemical analysis of primary and secondary structural elements (collagen, elastin)
showed no evidence of modification (Fourier Transform IR Spectroscopy and Differential
Scanning Calorimetry), degradation (High Performance Liquid Chromatography) or
increased enzyme degradation susceptibility. The hemodynamic function of the stenotic
AVs was improved (increased effective orifice areas up to 34.5±10.1% and decreased
transvalvular pressure gradients up to 46.2±9.9%). These changes were associated with
mineral removal (up to 117.0 ± 75.1 mg). Ovine AVs revealed some leaflet thinning and
slight regurgitation, of no clinical significance, through 9 months follow-up.
CONCLUSIONS – Mineral removal from calcified stenotic AVs improves leaflet mobility
and reduces transvalvular gradients while preserving tissue structure. Efficacy and safety
of in situ AV treatment has been demonstrated in both ex vivo and in vivo models. Effec-
tive calcified AV repair can be accomplished with an endoaortic treatment system.
1125-136 Predictive Factors of Peri and Post Operative Outcome 
After Valve Replacement in Patients With Critical Aortic 
Stenosis and Very Low Ejection Fraction
Bruno Vaquette, Herve Corbineau, Marcel Laurent, Bernard Lelong, Thierry Langanay, 
Christian de Place, Jean Philippe Verhoye, Christophe leclercq, Jean-Claude Daubert, 
Alain Leguerrier, University Hospital Rennes, Rennes, France
Background: Critical aortic stenosis with severe left ventricular systolic dysfunction
(LVSD) is classically associated with a high operative mortality. Moreover post-operative
LVSD reversibility is uncertain and difficult to predict. The aim of this restrospective study
was to identify the predictive factors of post-operative mortality and LVSD reversibility.
Methods and results: From 1990 to 2000, 155 consecutive pts (72±9 yrs) underwent
aortic valve replacement [AVR] for critical AS (mean gradient: 43±13 mmHg), with severe
LVSD (LVEF<30%). 138 pts were in NYHA class III-IV.
The peri-operative (30-day) mortality rate was 12%. NYHA class III-IV (p=0,004), cardio-
thoracic ratio > 0.6 [CTR] (p< 0, 0001), left bundle branch block (p=0,03) and renal insuf-
ficiency (p=0,001) were found as predictors of peri-operative mortality in univariate analy-
sis. At multivariate analysis, the only predictive factor was CTR >0,6 (p=0,002).
Pre PHV Post PHV 1-week follow-up
AVA (cm2) 0.57 ± 0.15 1.67 ± 0.15 * 1.54 ± 0.22 *
MG (mmHg) 29 ± 9 8 ± 3 * 12 ± 3 *
LV EF (%) 24 ± 9 31 ± 5 * 39 ± 7 *












Early LVEF recovery as indicated by a gain >10% between post- (day 7) and pre-opera-
tive values was documented in 55/136 post-operative survivors. Multivariate analysis
showed that pre-operative CTR>0.60 (p=0,006) and the mean gradient (p=0,045), were
independent predictors of early LVSD reversibility.
During a mean follow-up [FU] time of 4,6±3 yrs, 50 (36%) pts died, 70 % from non-car-
diac cause. In multivariate analysis 3 independent predictors of postoperative mortality
were found: diabetes (p=0,003), age >75 yrs (p=0,004) and the absence of early LVEF
recovery (p=0,01). Additionally, the postoperative functional benefit was significantly
greater in pts with LVEF recovery.Conclusion: Despite a relatively high but acceptable
peri-operative mortality rate, the benefit of AVR in AS with severe LVSD is clearly impor-
tant. Early post-operative LVEF recovery is associated with significantly better outcome
regarding both symptoms and survival.
1125-137 Progression of Ascending Aortic Dilatation in 
Congenital Bicuspid Aortic Valve Patients: Assessment 
by Serial Magnetic Resonance Imaging
Benjamin Atkeson, Gian Novaro, Michael Lieber, Richard Grimm, Brian Griffin, Richard D 
White, Cleveland Clinic Foundation, Cleveland, OH
Progression of Ascending Aortic Dilatation in Congenital Bicuspid Aortic Valve Patients:
Assessment by Serial MRI.
Introduction – Congenital bicuspid aortic valve (BAV) patients have an associated aortop-
athy, with ascending aortic dilatation and increased risk of dissection. Data is limited
regarding the rates of dilatation in these patients.
Methods – We identified consecutive adult patients with a diagnosis of BAV, who under-
went serial magnetic resonance imaging (MRI) of the aorta, at least 12 months apart.
Patients with prior aortic valve surgery were excluded. Demographic and echocardio-
graphic data, including beta blocker use was obtained by chart review. Aortic measure-
ments were made at the level of the sinuses and mid-ascending aorta.
Results – 66 BAV patients were identified (80% male; mean age 53 yrs). Mean follow-up
was 32 months (range 12-96). The mean annualized increase in aortic dilatation at the
sinuses was .8 mm/yr. Those with aortic regurgitation showed increased rates of dilata-
tion compared to those with normal and stenotic BAV(p=.05). No association was noted
between beta blocker use and rates of dilatation.
Conclusions- BAV patients have aortic dilatation, irrespective of valve dysfunction. In this
cohort BAV patients assessed by MRI, the average rates of ascending aortic dilatation
was 0.8mm/yr at the level of the sinuses, which is similar to prior reports. Those with aor-
tic regurgitation appear to have greater rates of progression, and may require closer
serial follow-up.
1125-138 N-Terminal Pro-Braintype Natriuretic Peptide in Patients 
With Aortic Valve Disease: Correlation to Surgical 
Result
Michael W. Weber, Roman Arnold, Matthias Rau, Christian Maikowski, Eva Keil, Roland 
Brandt, Vesselin Mitrovic, Christian Hamm, Kerckhoff Heart Center, Bad Nauheim, 
Germany
Background: The neurohormon NT-proBNP is secreted from the myocardium in
response to an increased left ventricular wall stress. As we have shown previously, NT-
proBNP is elevated in patients with aortic valve disease closely linked to disease severity
and clinical symptoms.
Hypothesis: Since NT-proBNP is elevated in patients with aortic stenosis (AS) and aortic
regurgitation (AR) it should decrease after successful aortic valve replacement (AVR) but
not in conservatively treated patients.
Methods: 92 patients (55 male; aged 67±11 years; EF>45%) with AS, AR or prior AVR
were included in the present study. Clinical symptoms, NT-proBNP and transaortic pres-
sure gradient (PG mean) were assessed at baseline and at follow up (9,9±0,6 months).
Values are given as mean±SD or SEM.
Results: AS was present in 64 patients (37 male, aged 69±11 years), AR in 17 patients
(10 male, aged 60±11 years), prior AVR in 11 patients (8 male, aged 67±7 years). 48
patients (40 AS, 8 AR) were surgically treated (AVR) and 44 patients (11 after prior AVR,
9 AR and 24 AS) were treated conservatively. NT-proBNP decreased remarkably in surgi-
cally treated patients with AS (3112±646 pg/ml to 845±175 pg/ml; p<0,01) and in patients
with AR (1575±861 pg/ml to 497±137 pg/ml; p < 0,01).There was no change in NT-
proBNP in conservatively treated patients with AS (885±293 pg/ml to 808±226 pg/ml;
ns), with AR (from 221±45 pg/ml to 484±276 pg/ml; ns) and in patients after prior AVR
(from 464±117 pg/ml to 745±226 pg/ml; ns). In patients with an improvement in clinical
symptoms (n=47) (at least one NYHA class) NT-proBNP decreased (2710±572 pg/ml to
912±178 pg/ml; p<0,01) whereas in patients with unchanged symptoms (n=25) NT-
proBNP levels did not change (574±132 pg/ml to 515±104 pg/ml; ns). In patients with a
worsening of clinical symptoms (n=15) NT-proBNP showed a tendency towards an
increase (478±163 pg/ml to 677±224 pg/ml; ns).
Conlusions: NT-proBNP is elevated in patients with aortic valve disease (AS and AR)
and decreases remarkably after successful surgical treatment closely linked to an
improvement in clinical symptoms. This underlines the usefulness of NT-proBNP as a
biochemical marker for the evaluation and monitoring of disease progression.
1125-139 Populations Benefiting From the Ross Procedure: A 
Long-Term Follow-Up
Pablo Stutzbach, Santiago Lynch, Pablo Roura, Alejandro Machaín, Roberto R. Favaloro, 
Institute of Cardiology and Cardiovascular Surgery of the Favaloro Foundation, Buenos 
Aires, Argentina
Background: The Ross procedure (RP) is a surgical alternative to mechanical prosthe-
ses or to bioprostheses for the treatment of aortic valve disease. However, not all patients
benefit from RP. The purpose of this study was to analyze the results at 90 months in
patients undergoing RP and to determine what populations were the most benefited.
Methods: From 1995 through 2003, 125 patients (mean age 38±13 years, 99 males)
underwent RP. Fifty-nine patients (47%) had severe aortic stenosis, 57 patients (46%)
had significant aortic regurgitation, 4 patients (3.2%) had active endocarditis, and 6 (5%)
patients had prosthetic dysfunction. Eighty-two patients (65%) had bicuspid aortic valve.
Pulmonary autograft and pulmonary homograft dysfunction was defined as >++/4 regur-
gitation or peak gradient >20 mmHg as registered by Doppler echocardiography.
Results: Hospital mortality was 3.2% (4 patients). Survival at 90 months was 96.3±1.8%.
Freedom from reoperation was 95.4±2.7%; from autograft explant, 97%±2.7%; from pul-
monary homograft explant, 99±1.3%; from autograft dysfunction, 87±3.6%; from pulmo-
nary homograft dysfunction, 73±7.2%; from endocarditis, 99±1.1%; and from
thromboembolism and bleeding, 100%. Patients with aortic valve regurgitation had a
higher tendency toward autograft dysfunction than patients with aortic stenosis (78±8%
versus 100%, P=.004).Patients with age <30 years had a higher tendency toward pulmo-
nary homograft dysfunction than patients with age >30 years (69±10% vs 90±5%
P=.001).On multivariate analysis (Cox test) no variables associated with mortality and
reoperation. However, previous aortic regurgitation associated with autograft dysfuntion
(OR 5.4, 95% CI 1.21-24.8, P=.027), and age <30 years (OR 0.9, 95% CI 0.86-0.95,
P=.001), with homograft dysfunction.
Conclusion: RP constitutes an alternative for patients with aortic valve stenosis and age
>30 years, since they present with a low rate of events at 90 months.
1125-140 Creases and Folds: Why Does the Bicuspid Aortic Valve 
Fail So Early?
Francis Robicsek, Mano J. Thubrikar, Joseph W. Cook, Mark K. Reames, Sr., Brett L. 
Fowler, Carolinas Heart Institute at Carolinas Medical Center, Charlotte, NC, Heineman 
Medical Research Laboratories, Carolinas Medical Center, Charlotte, NC
Background:Congenitally bicuspid aortic valves (CBAV) are the leading cause of clini-
cally manifest aortic valve disease in patients below the age of 50. The reason why
CBAV’s fail, however, has not been determined.
Methods: The subject has been investigated in vitro experiments as well as in computer-
digital simulation studies. Aortic roots containing bicuspid valve were obtained out of
young individuals who died of non-cardiac causes and had no clinically manifest aortic
valve disease. The specimens were freeze-dried shortly after death then thawed and
mounted in left heart simulator primed with glycerol solution and/or normal saline. Hemo-
dynamic parameters were monitored under different flow and pressure conditions. Valve
function was recorded and studied with both normal speed and with 800-frames/sec. cin-
ematography. Using the molds as a basis, morphology of the aortic root was recon-
structed by digital modeling and studied under different simulated conditions. Stress-
grids were constructed and stress was measured simulating function. The results of the
experiments were compared to those we have obtained in previous studies on the normal
tricuspid aortic valve.
Results: The principal findings are as follows:
1.  All congenitally bicuspid aortic roots are morphologically significantly stenotic 
even in absence of clinical symptoms and measurable pressure gradients.
1.  Congenitally bicuspid aortic valves show significant degree of creasing and 
folding even when fully expanded. This phenomenon further increases dur-
ing function.
1.  Contrary to the normal, tri-leaflet aortic valve, the folding of the leaflet edges of 
the CBAV is maximal in diastole, thus the diastolic pressure load exerted 
upon it is multiple of the normal.
Conclusions: The above phenomenon induces a significant stress overload, which 
undoubtedly contributes to the early failure rate of CBAV’s. 












Baseline Aortic Diameter  at 
Sinuses
43mm 42mm 45mm 43mm
Baseline Aortic Diameter at 
Ascending Aorta
47mm 51mm 43mm 46mm
Annualized rate of change at 
Sinuses (mm/yr)
.8 mm/yr .3 mm/yr 1.1 mm/yr .2 mm/yr
Annualized rate of change at 
Ascending Aorta (mm/yr)
.4 mm/yr .6 mm/yr .6 mm/yr .2 mm/yr
